Article Text

PDF
CP-208 Pegylated liposomal doxorubicin and carboplatine combination in the treatment of recurrent ovarian carcinoma. Comparative long term effectiveness
  1. M Miarons1,
  2. S Martínez2,
  3. V García1,
  4. S Marin1,
  5. ML Camps1,
  6. C Agustí1,
  7. T Gurrera1
  1. 1Mataro Hospital, Pharmacy, Mataro, Spain
  2. 2Mataro Hospital, Oncology, Mataro, Spain

Abstract

Background Pegylated liposomal doxorubicin (PLD) can be used in combination with carboplatin as a firstline treatment of advanced ovarian cancer or as monotherapy for the treatment of advanced ovarian cancer in women who have failed firstline platinum based chemotherapy regimen.

Purpose To compare the effectiveness of PLD in terms of biochemical progression free survival (BPFS) when used in monotherapy or in combination drug therapy.

Material and methods Retrospective observational study of all patients treated with PLD for ROC over a period of 3 years (2012–2015). Data were collected from medical records which also stored patient characteristics, their disease, treatment received and CA-125 levels. Effectiveness was mainly evaluated with BPFS. Descriptive statistical analysis and cohort comparison were done. Demographic and clinical parameters were collected from the clinical history.

Results 16 patients were included, with a mean age of 64 years (95% CI 45–79). Stage III or higher was present in 15 (94%) patients at diagnosis. The DLP-carboplatin combination was used in 69% (11), and 31% (5) received DLP monotherapy. In more than 90.0% of cases, PLD was used as secondline treatment.

Median BPFS in the DLP monotherapy group was 2.6 (13 weeks) versus 9.2 (46 weeks) in the DLP-carboplatin combination group (p = 0.031).

Conclusion The addition of PLD when treating ROC was associated with increases in BPFS. The benefit obtained was greater in the subgroup of patients with the carboplatin combination than with DLP monotherapy.

References and/or Acknowledgements

  1. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1–8

References and/or AcknowledgementsNo conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.